Adagio Medical Holdings, Inc. is a medical device company developing and placing on the European Union (EU) market ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio consists of three product families: iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories. All of these catheters share the same ULTC cryoablation console. A standalone PFA console connected to a cryoablation console for PFCA treatment synchronization is used in conjunction with Cryopulse catheter. The iCLAS system is CE-marked with the indication for treatment of paroxysmal atrial fibrillation, persistent atrial fibrillation and atrial flutter. The vCLAS ventricular catheter has been specifically designed for treatment of the ventricular arrhythmia. Its product offerings consist largely of the single use ablation catheters and consoles.
Ticker SymbolADGM
Company nameAdagio Medical Holdings Inc
IPO dateFeb 26, 2021
CEOMr. Todd Usen
Number of employees86
Security typeOrdinary Share
Fiscal year-endFeb 26
Address26051 Merit Circle
CityLAGUNA HILLS
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92653
Phone12122842300
Website
Ticker SymbolADGM
IPO dateFeb 26, 2021
CEOMr. Todd Usen
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data